Sistema de Salut de Catalunya
Institut Català de la Salut
[de Melo Gagliato D] Centro Oncológico Antonio Ermírio de Moraes, Beneficência Portuguesa de São Paulo, São Paulo, Brazil. [Buzaid AC] Centro Oncológico Antonio Ermírio de Moraes, Beneficência Portuguesa de São Paulo, São Paulo, Brazil. Centro Oncológico Hospital Israelita Albert Eisntein, São Paulo, Brazil. [Perez-Garcia JM, Llombart A] Baselga Institute of Oncology, Quiron University Hospital Barcelona, Barcelona, Spain. [Cortes J] Ramon y Cajal University Hospital, Madrid, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2021-08-26T11:40:50Z
2021-08-26T11:40:50Z
2020-09-01
Inhibidors de CDK4/6; Càncer de mama amb receptor hormonal positiu; Càncer de mama metastàtic
Inhibidores de CDK4/6; Cáncer de mama con receptor hormonal positivo; Cáncer de mama metastásico
CDK4/6 inhibitors; Hormone receptor-positive breast cancer; Metastatic breast cancer
Treatment paradigms in advanced hormone receptor (HR)-positive breast cancer were substantially transformed with cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) approval. The addition of these drugs to endocrine treatment profoundly improved progression-free and overall survival. Additionally, other important endpoints, such as the response rate, time to chemotherapy, and a delay in quality of life deterioration, were positively impacted by CDK4/6 inhibitors’ addition to the treatment of advanced HR-positive breast cancer. This review article will summarize current knowledge on CDK4/6 inhibitors in clinical practice for advanced HR-positive metastatic breast cancer, as well as describe recent efforts to more precisely characterize mechanisms of sensitivity and resistance to these drugs, both on the molecular and clinical characterization level.
This research received no external funding.
Artículo
Versión publicada
Inglés
Mama - Càncer; Medicaments antineoplàstics - Ús terapèutic; DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms; CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents; Other subheadings::Other subheadings::/therapeutic use; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama; COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos; Otros calificadores::Otros calificadores::/uso terapéutico
MDPI
Cancers;12(9)
https://www.mdpi.com/2072-6694/12/9/2480
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
